BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:02 PM
Sep 25, 2007
 |  BC Extra  |  Clinical News

AstraZeneca presents ZD4054 data

AstraZeneca (LSE:AZN; AZN) said ZD4054 missed the primary endpoint of progression free survival vs. placebo in a double-blind Phase...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >